Quantcast

Latest Intraocular pressure Stories

2009-02-25 08:00:00

LAWRENCEVILLE, N.J., Feb. 25 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has acquired the U.S. marketing rights to the TIMOPTIC(R) product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle...

2009-02-19 12:15:00

- Clinical Performance Indicates a 40% Reduction of Intraocular Pressure at Two Years - WALTHAM, Mass., Feb. 19 /PRNewswire/ -- SOLX, Inc. announced today that it has surpassed 1000 implantation procedures with its proprietary SOLX Gold Shunt(R), a drainage device that reduces intraocular pressure (IOP) for the treatment of glaucoma. "This is a significant milestone," said Doug Adams, President and Founder of SOLX, "as it validates the importance of the Gold Shunt in the treatment of...

2009-02-12 06:52:00

The New York Eye and Ear Infirmary Joins International Observance To Draw Attention To "The Sneak Thief of Sight" NEW YORK, Feb. 12 /PRNewswire-USNewswire/ -- In an effort to combat one of the leading causes of blindness worldwide, the World Glaucoma Association and the World Glaucoma Patient Organization have set March 12, 2009, as the second annual World Glaucoma Day. The day will be marked by awareness and educational events organized by eye care institutions and local patient support...

9068bc0e7992d05a26c5e7a52803ebe01
2009-01-29 10:09:20

Yearly screening that can lead to early detection of glaucoma can help prevent long-term damage to eye sight, ophthalmologists at Baylor College of Medicine in Houston advised. "The biggest problem with glaucoma is that it's a silent disease, a 'sneak thief of sight'," said Dr. Silvia Orengo-Nania, professor of ophthalmology in the Baylor Eye Clinic at BCM. "You could have visual damage occurring over time and not know it. Once damage occurs, it is irreversible and you will not be able to get...

2008-11-14 12:00:22

Inotek Pharmaceuticals, a clinical-stage, drug-development company, has announced that the US Patent and Trademark Office has issued two new patents covering the company's two lead clinical compounds INO-8875 and INO-4885. INO-8875 is a selective adenosine 1 agonist in Phase I clinical development as a topical agent for the treatment of elevated intraocular pressure associated with primary open angle glaucoma and ocular hypertension. INO-4885 is a peroxynitrite decomposition catalyst in...

2008-11-13 12:00:25

Inotek Pharmaceuticals Corporation announced today that the United States Patent and Trademark Office has issued two new patents covering the Company's two lead clinical compounds. US Patent number 7,423,144 relates to INO-8875, in clinical development as a novel treatment for glaucoma and US Patent number 7,432,369 relates to INO-4885, in clinical development for the prevention of contrast-induced nephropathy. "These patents cover important technology discovered and developed by Inotek...

2008-10-30 09:00:40

Hi-Tech Pharmacal, a specialty pharmaceutical company, has announced that the FDA has granted final approval to the company's abbreviated new drug application for dorzolamide and timolol ophthalmic solution, the generic for Merck's Cosopt. The product is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta blockers. Hi-Tech plans to launch generic dorzolamide and timolol ophthalmic...

2008-09-16 09:00:53

Othera Pharmaceuticals, a specialty pharmaceutical company, has initiated dosing in a Phase I/II clinical trial to determine the safety and efficacy of topical OT-730 in patients with ocular hypertension and glaucoma. The study is a randomized, multi-center, investigator-masked, timolol- and placebo-controlled evaluation of the safety and efficacy of OT-730 in reducing the intraocular pressure in subjects with ocular hypertension or open-angle glaucoma. Subjects will be randomized to one of...

2008-09-15 12:00:35

Othera Pharmaceuticals, Inc., today announced that it has initiated dosing in a Phase I/II clinical trial to determine the safety and efficacy of topical OT-730 in patients with ocular hypertension and glaucoma. The study is a randomized, multi-center, investigator-masked, timolol- and placebo-controlled evaluation of the safety and efficacy of OT-730 in reducing the intraocular pressure in subjects with ocular hypertension or open-angle glaucoma. Subjects will be randomized to one of 0.75%...

2008-09-12 12:00:35

US-based biopharmaceutical company Inspire Pharmaceuticals has announced that the standard 30-day review period by the FDA relating to the company's investigational new drug application for INS117548 ophthalmic solution for the treatment of glaucoma has concluded and clinical testing can proceed. Inspire is currently targeting the initiation of a Phase I clinical trial by the end of 2008 to evaluate the tolerability and efficacy of this product candidate in subjects with early stage...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related